Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

JERSEY CITY, N.J.--(BUSINESS WIRE)--Oct 22, 2023--

Related Keywords

New Jersey ,United States ,Jersey ,Thomas Nusbickel ,Jean Frederic Colombel ,Lindsey Lucenta ,Andres Yarur ,Public Health Service Act ,Sinai Medical Center ,Drug Administration ,Icahn School Of Medicine At Mount Sinai ,European Commission ,Celltrion United States ,Biologics License Application ,Chief Commercial Officer ,Celltrion United ,Icahn School ,Cedars Sinai Medical ,Celltrion Healthcare ,Important Safety ,Business Wire ,Business ,